OAC3
目录号 : GC10724
An Oct4-activating compound
Cas No.:182564-41-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
OAC3 is identified as an activator of octamer-binding transcription factor 4.
Octamer-binding transcription factor 4 (Oct4), a key regulator of embryonic stem cell (ESC) pluripotency, is cirtical to the reprogramming process.
In vitro: OAC3 was shown to be able to activate both Oct4 and Nanog reporters to a similar extent as OAC1, which was its analog with greatest activating effects on both Oct4 and Nanog promoter-driven luciferase reporter genes. It was also found that both OAC1 and OAC3 could considerably enhance the 4F-induced reprogramming efficiency. Furthermore, OAC1 and OAC3 enhanced reprogramming efficiency four-fold, up to as high as 2.75%, and also accelerated the appearance of iPSC colonies 3 to 4 d when used in combination with the four reprogramming factors, which were Oct4, Sox2, Klf4, and c-Myc [1].
In vivo: In animal to test the in vivo pluripotency of the 4F+OAC2-induced iPSCs, which was another OAC3 analog, the 4F+OAC2-iPSCs were transplanted the into immunodeficient Nude mice. Results showed that 4 to 6 weeks after transplantation, 4F+OAC2-iPSCs generated typical teratomas containing derivative of three germ layers effectively, such as epidermis of ectoderm, blood of mesoderm, and intestinal epithelia of endoderm [1].
Clinical trial: Up to now, OAC3 is still in the preclinical development stage.
Reference:
[1] Li W,Tian E,Chen ZX,Sun G,Ye P,Yang S,Lu D,Xie J,Ho TV,Tsark WM,Wang C,Horne DA,Riggs AD,Yip ML,Shi Y. Identification of Oct4-activating compounds that enhance reprogramming efficiency. Proc Natl Acad Sci U S A.2012 Dec 18;109(51):20853-8.
| Cas No. | 182564-41-6 | SDF | |
| 化学名 | 4-fluoro-N-(1H-indol-5-yl)benzamide | ||
| Canonical SMILES | O=C(C1=CC=C(C=C1)F)NC2=CC=C3NC=CC3=C2 | ||
| 分子式 | C15H11FN2O | 分子量 | 254.26 |
| 溶解度 | DMF: 20 mg/ml,DMF:PBS(pH 7.2)(1:1): 0.50 mg/ml,DMSO: 16 mg/ml,Ethanol: 12.5 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.933 mL | 19.6649 mL | 39.3298 mL |
| 5 mM | 0.7866 mL | 3.933 mL | 7.866 mL |
| 10 mM | 0.3933 mL | 1.9665 mL | 3.933 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。